Literature DB >> 23473961

First therapeutic use of Artesunate in treatment of human herpesvirus 6B myocarditis in a child.

Nina Hakacova1, Karin Klingel, Reinhard Kandolf, Elin Engdahl, Anna Fogdell-Hahn, Thomas Higgins.   

Abstract

BACKGROUND: Human herpesvirus 6 (HHV-6) is an important cause of fulminant or acute viral myocarditis. However, insufficiency of standard antiviral treatment against HHV-6 is an emerging problem.
OBJECTIVES: To describe the case of child with HHV-6 myocarditis who was treated by unloading with a left ventricular assist device and Artesunate. STUDY
DESIGN: Case report supported by histological and viral diagnoses via a combination of histology/immunohistochemistry and polymerase chain reaction techniques performed on cardiac tissues before and after treatment.
RESULTS: Following therapeutic intervention, the clinical status and heart function improved. Endomyocardial biopsies revealed decreased levels of HHV-6B DNA in the myocardium and the disappearance of histological findings in support of lymphocytic myocarditis. Left ventricular assist device could be explanted. No adverse effects of Artesunate were noted.
CONCLUSIONS: In addition to existing heart failure treatments, Artesunate can be considered as an effective candidate for clinical use in cases of HHV-6B associated myocarditis.
Copyright © 2013 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23473961     DOI: 10.1016/j.jcv.2013.02.005

Source DB:  PubMed          Journal:  J Clin Virol        ISSN: 1386-6532            Impact factor:   3.168


  18 in total

1.  Antiviral effects of artesunate on JC polyomavirus replication in COS-7 cells.

Authors:  Biswa Nath Sharma; Manfred Marschall; Christine Hanssen Rinaldo
Journal:  Antimicrob Agents Chemother       Date:  2014-08-25       Impact factor: 5.191

2.  Fatal Myocarditis Associated With HHV-6 Following Immunosuppression in Two Children.

Authors:  Heather E Stefanski; Kathryn A Thibert; Joshua Pritchett; Bhupesh K Prusty; John E Wagner; Troy C Lund
Journal:  Pediatrics       Date:  2015-12-17       Impact factor: 7.124

Review 3.  The development of new therapies for human herpesvirus 6.

Authors:  Mark N Prichard; Richard J Whitley
Journal:  Curr Opin Virol       Date:  2014-10-22       Impact factor: 7.090

Review 4.  Laboratory and clinical aspects of human herpesvirus 6 infections.

Authors:  Henri Agut; Pascale Bonnafous; Agnès Gautheret-Dejean
Journal:  Clin Microbiol Rev       Date:  2015-04       Impact factor: 26.132

Review 5.  Human herpesvirus-6 encephalitis after allogeneic hematopoietic cell transplantation: what we do and do not know.

Authors:  M Ogata; T Fukuda; T Teshima
Journal:  Bone Marrow Transplant       Date:  2015-04-27       Impact factor: 5.483

Review 6.  Management of fulminant myocarditis: a diagnosis in search of its etiology but with therapeutic options.

Authors:  Bernhard Maisch; Volker Ruppert; Sabine Pankuweit
Journal:  Curr Heart Fail Rep       Date:  2014-06

7.  Antiviral effects of artesunate on polyomavirus BK replication in primary human kidney cells.

Authors:  Biswa Nath Sharma; Manfred Marschall; Stian Henriksen; Christine Hanssen Rinaldo
Journal:  Antimicrob Agents Chemother       Date:  2013-10-21       Impact factor: 5.191

Review 8.  Post-allogeneic hematopoietic stem cell transplantation viral reactivations and viremias: a focused review on human herpesvirus-6, BK virus and adenovirus.

Authors:  Xin Wang; Shyam A Patel; Michael Haddadin; Jan Cerny
Journal:  Ther Adv Infect Dis       Date:  2021-05-24

Review 9.  Modulatory effects on dendritic cells by human herpesvirus 6.

Authors:  Rasmus Gustafsson; Mattias Svensson; Anna Fogdell-Hahn
Journal:  Front Microbiol       Date:  2015-04-30       Impact factor: 5.640

10.  Subchronic toxicological study of two artemisinin derivatives in dogs.

Authors:  Ji-ye Yin; He-mei Wang; Quan-jun Wang; Yan-sheng Dong; Gang Han; Yong-biao Guan; Ke-yong Zhao; Wen-sheng Qu; Ye Yuan; Xiao-xin Gao; Shu-fang Jing; Ri-gao Ding
Journal:  PLoS One       Date:  2014-04-16       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.